

93 Contin. 20. A method as defined in claim 13, wherein said fish protein is cod fish.

24. A composition as defined in claim 22, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.

25. A composition as defined in claim 22, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

29. A method as defined in claim 26, wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.

A marked-up version of the amended claims is attached and entitled *Version With Markings to Show Changes Made*.

Please add the following claims 31-71:

31. A composition as defined in claim 2, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.

32. A composition as defined in claim 2, wherein said fish protein is cod fish protein.

33. A composition as defined in claim 3, wherein said fish protein is cod fish protein.

34. A composition as defined in claim 31, wherein said fish protein is cod fish protein.

35. A use as defined in claim 7, wherein said fish protein is cod fish protein.

36. A use as defined in claim 8, wherein said fish protein is cod fish protein.

37. A use as defined in claim 9, wherein said fish protein is cod fish protein.

38. A use as defined in claim 10, wherein said fish protein is cod fish protein.

39. A use as defined in claim 11, wherein said fish protein is cod fish protein.

40. A method as defined in claim 14, wherein said insulin resistance or hyperglycemia is the result of type 1 or Type 2 diabetes.

41. A method as defined in claim 16, wherein said insulin resistance or

hyperglycemia is the result of type 1 or Type 2 diabetes.

42. A method as defined in claim 17, wherein said insulin resistance or hyperglycemia is the result of type 1 or Type 2 diabetes.

43. A method as defined in claim 14, wherein said fish protein is cod fish.

44. A method as defined in claim 15, wherein said fish protein is cod fish.

45. A method as defined in claim 16, wherein said fish protein is cod fish.

46. A method as defined in claim 17, wherein said fish protein is cod fish.

47. A method as defined in claim 18, wherein said fish protein is cod fish.

48. A method as defined in claim 19, wherein said fish protein is cod fish.

49. A method as defined in claim 40, wherein said fish protein is cod fish.

50. A method as defined in claim 41, wherein said fish protein is cod fish.

51. A method as defined in claim 42, wherein said fish protein is cod fish.

52. A composition as defined in claim 23, wherein said hyperglycemia and insulin resistance are the result of Type 1 or Type 2 diabetes.

53. A composition as defined in claim 23, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

54. A composition as defined in claim 24, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

55. A composition as defined in claim 52, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

56. A method as defined in claim 27, wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.

57. A method as defined in claim 28, wherein said insulin resistance or hyperglycemia is the result of Type 1 or Type 2 diabetes.

58. A method as defined in claim 56, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

59. A method as defined in claim 57, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

a b
cont.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

60. A composition as defined in claim 32, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

61. A composition as defined in claim 33, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

62. A composition as defined in claim 34, further comprising a pharmaceutically-acceptable carrier, adjuvant or vehicle.

63. A method as defined in claim 43, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

64. A method as defined in claim 44, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

65. A method as defined in claim 45, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

66. A method as defined in claim 46, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

67. A method as defined in claim 47, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

68. A method as defined in claim 48, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

69. A method as defined in claim 49, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

70. A method as defined in claim 50, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

71. A method as defined in claim 51, wherein said compounds are combined with a pharmaceutically-acceptable carrier, adjuvant or vehicle.

Please add the attached Abstract of the Disclosure.